Advertisement

Current HIV/AIDS Reports

, Volume 7, Issue 4, pp 220–225 | Cite as

Drug Treatment as HIV Prevention: Expanding Treatment Options

  • David S. MetzgerEmail author
  • Yan Zhang
Article

Abstract

Research conducted during the first 20 years of the AIDS epidemic provided a solid foundation of data supporting methadone treatment as HIV prevention. Drug users in methadone treatment were consistently found to reduce the frequency of drug use, risk behaviors, and infections. These data have been consistent over time and across cultural settings and have been used to promote the expansion of drug treatment as a prevention intervention. More recently, data have emerged suggesting the prevention potential of medication-assisted treatments other than methadone (buprenorphine/naloxone and naltrexone). Still, with a few notable exceptions, global drug treatment coverage for opiate injectors remains remarkably low and only a few treatment interventions for stimulant use have shown efficacy in reducing HIV risk. Importantly, more recent data provide support for the role of drug treatment programs in improving access and adherence to antiretroviral treatment and that injection drug users in substance abuse treatment are more likely to achieve sustained viral suppression. While important challenges remain in maximizing its impact, the scientific literature provides strong evidence of the efficacy of drug treatment as an HIV prevention strategy.

Keywords

Substance abuse treatment HIV prevention Methadone Naltrexone Buprenorphine 

Notes

Acknowledgments

Preparation of this manuscript was supported in part by the following grants: U01-AI-048014, Penn Prevention Clinical Trials Unit (Metzger, PI); RO1-DA-026344-01A1 (Metzger, PI); and 6-P30-AI-45008 (Hoxie, PI).

Disclosure

No potential conflicts of interest relevant to this article were reported.

References

Papers of particular interest, published recently, have been highlighted as: •• Of major importance

  1. 1.
    Metzger DS, Navaline H, Woody GE: Drug abuse treatment as AIDS prevention. Public Health 1999, 113:97–106.Google Scholar
  2. 2.
    Gowing LR, Farrell M, Bornemann R, et al.: Methadone treatment of injecting opioid users for prevention of HIV infection. J Gen Intern Med 2006, 21:193–195.PubMedGoogle Scholar
  3. 3.
    Sorensen JL, Copeland AL: Drug abuse treatment as an HIV prevention strategy: a review. Drug Alcohol Depend 2000, 59:17–31.CrossRefPubMedGoogle Scholar
  4. 4.
    Ball JC, Lange WR, Myers CP, Friedman SR: Reducing the risk of AIDS through methadone-maintenance treatment. J Health Soc Behav 1988, 29:214–226.CrossRefPubMedGoogle Scholar
  5. 5.
    Qian HZ, Hao C, Ruan YH, et al.: Impact of methadone on drug use and risky sex in China. J Subst Abuse Treat 2008, 34:391–397.CrossRefPubMedGoogle Scholar
  6. 6.
    Caplehorn JRM, Ross MW: Methadone-maintenance and the likelihood of risky needle-sharing. Int J Addict 1995, 30:685–698.PubMedGoogle Scholar
  7. 7.
    Metzger DS, Woody GE, McLellan AT, et al.: Human-immunodeficiency-virus seroconversion among intravenous-drug-users in-of-treatment and out-of-treatment - an 18-month prospective follow-up. J Acquir Immune Defic Syndr Hum Retrovirol 1993, 6:1049–1056.Google Scholar
  8. 8.
    McLellan AT, Arndt IO, Metzger DS, et al.: The effects of psychosocial services in substance-abuse treatment. JAMA 1993, 269:1953–1959.CrossRefPubMedGoogle Scholar
  9. 9.
    Avants SK, Margolin A, Sindelar JL, et al.: Day treatment versus enhanced standard methadone services for opioid-dependent patients: A comparison of clinical efficacy and cost. Am J Psych 1999, 156:27–33.Google Scholar
  10. 10.
    Avants SK, Margolin A, Usubiaga MH, Doebrick C: Targeting HIV-related outcomes with intravenous drug users maintained on methadone: A randomized clinical trial of a harm reduction group therapy. J Subst Abuse Treat 2004, 26:67–78.CrossRefPubMedGoogle Scholar
  11. 11.
    Wong KH, Lee SS, Lim WL, Low HK: Adherence to methadone is associated with a lower level of HIV-related risk behaviors in drug users. J Subst Abuse Treat 2003, 24:233–239.CrossRefPubMedGoogle Scholar
  12. 12.
    Barnett PG, Sorensen JL, Wong W, et al.: Effect of incentives for medication adherence on health care use and costs in methadone patients with HIV. Drug Alcohol Depend 2009, 100:115–121.CrossRefPubMedGoogle Scholar
  13. 13.
    Thiede H, Hagan H, Murrill CS: Methadone treatment and HIV and hepatitis B and C risk reduction among injectors in the Seattle area. J Urban Health Bull N Y Acad Med 2000, 77:331–345.Google Scholar
  14. 14.
    World Health Organization: AIDS epidemic update: November 2009. WHO Library Cataloguing-in-Publication Data.Google Scholar
  15. 15.
    Bao YP, Liu ZM: Systematic review of HIV and HCV infection among drug users in China. Int J STD AIDS 2009, 20:399–405.CrossRefPubMedGoogle Scholar
  16. 16.
    Li J HT, Zhang C, Liu H, et al.: The Chinese government’s response to drug use and HIV/AIDS: A review of policies and programs. Harm Reduct J 2010, 7:4.CrossRefPubMedGoogle Scholar
  17. 17.
    Fiellin DA, Pantalon MV, Chawarski MC, et al.: Counseling plus buprenorphine-naloxone maintenance therapy for opioid dependence. N Engl J Med 2006, 355:365–374.CrossRefPubMedGoogle Scholar
  18. 18.
    Bridge TP, Fudala PJ, Herbert S, Leiderman DB: Safety and health policy considerations related to the use of buprenorphine/naloxone as an office-based treatment for opiate dependence. Drug Alcohol Depend 2003, 70(2 Suppl):S79–S85.CrossRefPubMedGoogle Scholar
  19. 19.
    Sullivan LE, Fiellin DA: Buprenorphine: Its role in preventing HIV transmission and improving the care of HIV-infected patients with opioid dependence. Clin Infect Dis 2005, 41:891–896.CrossRefPubMedGoogle Scholar
  20. 20.
    Sullivan LE, Metzger DS, Fudala PJ, Fiellin DA: Decreasing international HIV transmission: the role of expanding access to opioid agonist therapies for injection drug users. Addiction 2005, 100:150–158.CrossRefPubMedGoogle Scholar
  21. 21.
    Sullivan LE, Moore BA, Chawarski MC, et al.: Buprenorphine/naloxone treatment in primary care is associated with decreased human immunodeficiency virus risk behaviors. J Subst Abuse Treat 2008, 35:87–92.CrossRefPubMedGoogle Scholar
  22. 22.
    Meade CS, Weiss RD, Fitzmaurice GM, et al.: HIV risk behavior in treatment-seeking opioid-dependent youth: results from a NIDA Clinical Trials Network Multisite Study. J Acquir Immune Defic Syndr 2010, In press.Google Scholar
  23. 23.
    Schackman BR, Merrill JO, McCarty D, et al.: Overcoming policy and financing barriers to integrated buprenorphine and HIV primary care. Clin Infect Dis 2006, 43:S247–S253.CrossRefPubMedGoogle Scholar
  24. 24.
    Doran CM, Shanahan M, Mattick RP, et al.: Buprenorphine versus methadone maintenance: a cost-effectiveness analysis. Drug Alcohol Depend 2003, 71:295–302.CrossRefPubMedGoogle Scholar
  25. 25.
    Schottenfeld RS, Chawarski MC, Mazlan M: Maintenance treatment with buprenorphine and naltrexone for heroin dependence in Malaysia: a randomised, double-blind, placebo-controlled trial. Lancet 2008, 371:2192–2200.CrossRefPubMedGoogle Scholar
  26. 26.
    Krupitsky EM, Zvartau EE, Masalov DV, et al.: Naltrexone with or without fluoxetine for preventing relapse to heroin addiction in St. Petersburg, Russia. J Subst Abuse Treat 2006, 31:319–328.CrossRefPubMedGoogle Scholar
  27. 27.
    Vermund SH, Hodder SL, Justman JE, et al.: Addressing research priorities for prevention of HIV infection in the United States. Clin Infect Dis 2010, 50:S149–S155.CrossRefPubMedGoogle Scholar
  28. 28.
    Lima VD, Johnston K, Hogg RS, et al.: Expanded access to highly active antiretroviral therapy: A potentially powerful strategy to curb the growth of the HIV epidemic. J Infect Dis 2008, 198:59–67.CrossRefPubMedGoogle Scholar
  29. 29.
    Chander G, Himelhoch S, Fleishman JA, et al.: HAART receipt and viral suppression among HIV-infected patients with co-occurring mental illness and illicit drug use. AIDS Care 2009, 21:655–663.CrossRefPubMedGoogle Scholar
  30. 30.
    Krusi A, Wood E, Montaner J, Kerr T: Social and structural determinants of HAART access and adherence among injection drug users. Int J Drug Policy 2010, 21:4–9.CrossRefPubMedGoogle Scholar
  31. 31.
    Uhlmann S, Milloy MJ, Kerr T: Methadone maintenance therapy promotes initiation of antiretroviral therapy among injection drug users. Addicton 2010, 105:907–913.CrossRefGoogle Scholar
  32. 32.
    Lucas GM, Mullen BA, Weidle PJ, et al.: Directly administered antiretroviral therapy in methadone clinics is associated with improved HIV treatment outcomes, compared with outcomes among concurrent comparison groups. Clin Infect Dis 2006, 42:1628–1635.CrossRefPubMedGoogle Scholar
  33. 33.
    Lucas GM, Griswold M, Gebo KA, et al.: Illicit drug use and HIV-1 disease progression: a longitudinal study in the era of highly active antiretroviral therapy. Am J Epidemiol 2006, 163:412–420.CrossRefPubMedGoogle Scholar
  34. 34.
    •• Roux P, Carrieri MP, Villes V, et al.: The impact of methadone or buprenorphine treatment and ongoing injection on highly active antiretroviral therapy (HAART) adherence: evidence from the MANIF2000 cohort study. Addiction 2008, 103:1828–1836. This article is the first to demonstrate that the beneficial effects of medication-assisted treatment on adherence to antiretroviral treatment are only seen among those who respond to treatment and cease injection. For those in drug treatment who continue to inject drugs, adherence is similar to injectors not in drug treatment.CrossRefPubMedGoogle Scholar
  35. 35.
    Roux P, Carrieri MP, Cohen J, et al.: Retention in opioid substitution treatment: a major predictor of long-term virological success for HIV-infected injection drug users receiving antiretroviral treatment. Clin Infect Dis 2009, 49:1433–1440.CrossRefPubMedGoogle Scholar
  36. 36.
    Spire B, Lucas GM, Carrieri MP: Adherence to HIV treatment among IDUs and the role of opioid substitution treatment (OST). Int J Drug Policy 2007, 18:262–270.CrossRefPubMedGoogle Scholar
  37. 37.
    Bogart LM, Kral AH, Scott A, et al.: Condom attitudes and behaviors among injection drug users participating in California syringe exchange programs. AIDS Behav 2005, 9:423–432.CrossRefPubMedGoogle Scholar
  38. 38.
    Bogart LM, Kral AH, Scott A, et al.: Sexual risk among injection drug users recruited from syringe exchange programs in California. Sex Transm Dis 2005, 32:27–34.CrossRefPubMedGoogle Scholar
  39. 39.
    Bluthenthal RN, Do DP, Finch B, et al.: Community characteristics associated with HIV risk among injection drug users in the San Francisco Bay Area: a multilevel analysis. J Urban Health 2007, 84:653–666.CrossRefPubMedGoogle Scholar
  40. 40.
    Woody GE, VanEtten-Lee ML, McKirnan D, et al.: Substance use among men who have sex with men: Comparison with a national household survey. J Acquir Immune Defic Syndr 2001, 27:86–90.PubMedGoogle Scholar
  41. 41.
    Koblin B, Chesney M, Coates T, et al.: Effects of a behavioural intervention to reduce acquisition of HIV infection among men who have sex with men: the EXPLORE randomised controlled study. Lancet 2004, 364:41–50.CrossRefPubMedGoogle Scholar
  42. 42.
    Koblin BA, Husnik MJ, Colfax G, et al.: Risk factors for HIV infection among men who have sex with men. AIDS 2006, 20:731–739.CrossRefPubMedGoogle Scholar
  43. 43.
    •• Meader N, Li R, Des Jarlais DC, Pilling S: Psychosocial interventions for reducing injection and sexual risk behaviour for preventing HIV in drug users. Cochrane Database Syst Rev 2010, 1:CD007192. This article reports on a comprehensive meta-analysis of the published literature on psychosocial interventions to reduce risk behaviors among drug users. The conclusions of this article are that psychosocial interventions alone have only moderate evidence of efficacy. The findings support the importance of linking psychosocial interventions to efficacious interventions such as drug treatment, antiretroviral treatment, and needle exchange programs.PubMedGoogle Scholar
  44. 44.
    Tross S, Campbell ANC, Cohen LR, et al.: Effectiveness of HIV/STD sexual risk reduction groups for women in substance abuse treatment programs: Results of NIDA clinical trials network trial. J Acquir Immune Defic Syndr 2008, 48:581–589.CrossRefPubMedGoogle Scholar
  45. 45.
    Calsyn DA, Hatch-Maillette M, Tross S, et al.: Motivational and skills training HIV/sexually transmitted infection sexual risk reduction groups for men. J Subst Abuse Treat 2009, 37:138–150.CrossRefPubMedGoogle Scholar
  46. 46.
    Calsyn DA, Crits-Christoph P, Hatch-Maillette MA, et al.: Reducing sex under the influence of drugs or alcohol for patients in substance abuse treatment. Addiction 2010, 105:100–108.CrossRefPubMedGoogle Scholar
  47. 47.
    •• Mathers BM, Degenhardt L, Ali H, et al.: HIV prevention, treatment, and care services for people who inject drugs: a systematic review of global, regional, and national coverage. Lancet 2010, 375:1014–1028. This article provides current estimates of the prevention, drug treatment, and HIV treatment services available to drug users globally. The message is clear and sobering—in all regions of the world needs for services far outstrip the availability of those services. These data support the need to both expand coverage of existing treatment strategies and to develop new approaches that are acceptable, accessible, and affordable.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2010

Authors and Affiliations

  1. 1.HIV/AIDS Prevention Research DivisionUniversity of PennsylvaniaPhiladelphiaUSA

Personalised recommendations